Answers are grounded in this paper and cite their sources.
INTRODUCTION: Complement inhibitors have transformed outcomes in paroxysmal nocturnal hemoglobinuria (PNH), with intravenous (IV) C5 inhibitors resulting in sustained hemolysis control, reduced thrombotic risk, and improved survival. Ongoing IV infusions, however, can be burdensome for some patients, and terminal complement blockade can result in clinically significant extravascular hemolysis (EVH) in a subset of patients. Four new self-administered agents, pegcetacoplan, iptacopan, crovalimab, and danicopan, have expanded the therapeutic landscape in PNH. AREAS COVERED: This review draws on pivotal trial data, patient-reported outcome analyses, and real-world evidence to examine the current clinical role of each agent. We searched PubMed and Google Scholar with no date range limitations, supplemented by hematology conference abstracts and regulatory documents. We weigh patient-centered benefits against clinically relevant risks, including adherence, infection risk, breakthrough hemolysis, and limited pregnancy data. We offer a practical framework for approaching self-administered therapies in PNH. EXPERT OPINION: Self-administered therapies expand options for individualized PNH care, but greater autonomy shifts responsibility for adherence and complication recognition onto patients, underscoring the continued need for structured education, patient support programs, and specialist oversight. Longer-term real-world data, particularly on adherence, breakthrough hemolysis, and pregnancy, are needed to guide patient selection and further support use of these agents.
No takes yet. Share an insight, caveat, or question.
Chin-Yee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: